Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial
John W. Ostrominski(Brigham and Women's Hospital), Scott D. Solomon(Brigham and Women's Hospital), Brian Claggett(National Heart Lung and Blood Institute), Anna Maria Langkilde(AstraZeneca (Sweden)), Adrian F. Hernandez(Duke University), Pardeep S. Jhund(Copenhagen University Hospital), John J.V. McMurray(University of Glasgow), Senthil Selvaraj(Duke University), Rudolf A. de Boer(Erasmus MC), Felipe A. Martínez(Universidad Nacional de Córdoba), Mikhail Kosiborod(AstraZeneca (Brazil)), Muthiah Vaduganathan(Brigham and Women's Hospital), Carolyn S.P. Lam(University of Glasgow), Magnus Petersson(Sahlgrenska University Hospital), Zi Michael Miao(Brigham and Women's Hospital), Silvio E. Inzucchi(Yale University), Akshay S. Desai(Brigham and Women's Hospital), Sanjiv J. Shah(Northwestern University)
Cited by 20
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
|New England Journal of Medicine|2015|11.9k
Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology
|Journal of the American Society of Echocardiography|2005|11.3k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k